Background
==========

Accountability and transparency in health care, at individual and institutional levels, has gained increasing importance in recent years \[[@B1]-[@B3]\]. This growing focus on quality of practise and safety of services has implications for patients, clinicians, administrators and policy makers. Quality assessments of hospital performance are now conducted routinely throughout the world, the results of which are made available to all stakeholders. Information of this kind has been used for the purposes of benchmarking, so as to improve performance across all institutions \[[@B4]\] and to empower the general public to make informed decisions about where they choose to receive care.

Surgical resection for curable oesophageal and gastro-oesophageal cancer is the mainstay of treatment for all patients who are fit for major surgery. However, despite being the only curative treatment for oesophageal/gastro-oesophageal cancer patients, oesophagectomy is associated with significant operative morbidity and mortality \[[@B5]-[@B7]\]. Key performance measures of oesophagectomy include 30-day mortality, hospital length-of-stay and post-surgery complication rate \[[@B8]-[@B17]\]. Factors influencing outcomes following oesophagectomy include hospital/surgeon factors (peer group/volume, surgical experience), tumour stage, histology and location, surgery type and patient comorbidity; with better outcomes reported in high volume hospitals, patients with non-metastatic disease (approximately 60% of patients), adenocarcinoma (the incidence of which is increasing), and when transhiatal oesophagectomy is performed \[[@B18]-[@B25]\].

In Australia, there has been keen interest in using administrative datasets to examine hospital performance \[[@B26]-[@B28]\] with surgeons, administrators and patients having endorsed independent review of surgical care \[[@B29]\]. We previously examined patient outcomes for oesophageal cancer following oesophagectomy in one Australian state using data linkage of administrative datasets \[[@B9]\]. We found oesophagectomy was performed with satisfactory outcomes however resection rates were lower than reported elsewhere, as other studies included cancer of the gastro-oesophageal junction in their analyses since gastro-oesophageal cancer is treated in a similar manner to oesophageal cancer \[[@B30],[@B31]\].

Therefore, our aim was to examine rates of oesophogectomy and post-resection outcomes for patients diagnosed with oesophageal cancer or gastro-oesophageal cancer in the state of New South Wales (NSW) between 2000 and 2007. Specifically, we examined the way in which the inclusion of gastro-oesophageal cancer to the oesophageal cancer cohort impacted on resection rates and post-resection outcomes.

Methods
=======

Setting
-------

Australia has a publicly-funded universal health care system and health care data is collected by Commonwealth and state-based jurisdictions. The Australian Government Department of Human Services administer the Medicare Benefits Scheme (MBS; which provides free or subsidised treatment by health professionals and fully subsidised treatment in public hospitals) and the Pharmaceutical Benefits Scheme (PBS; which provides subsidised access to prescription drugs). The individual state and territory health authorities are responsible for the collection of public and private hospital separation data within their jurisdiction. However, cross-jurisdictional data sets have not been linked routinely due to legislative and privacy issues.

Our current study uses routinely collected hospital separation data from New South Wales (NSW). NSW is the largest jurisdiction in Australia with eight area health districts (at the time this research commenced) and consists of more than 200 public and 80 private hospitals, some of which are in proximity to each other (co-located). As such medical specialists practise at both the public and affiliated private hospital.

Study population
----------------

Our study population consisted of patients with a primary invasive oesophageal and gastro-oesophageal cancer (International Classification of Diseases v3 \[ICD-O-3\] codes C15.0-C15.9 and C16.0).

Data sources and linkage
------------------------

We accessed and linked two population-based data sets in this study:

*NSW Central Cancer Registry (1 July 2000-31Dec2007)* - (CCR) receives notifications of cancer in NSW and maintains a record of all cancer cases diagnosed in NSW residents since 1972. The registry is managed according to the International Association of Cancer Registries (IACR) rules \[[@B32]\] and is one of the few Australian Cancer Registries to record degree-of-spread at first diagnosis for all solid malignant tumours \[[@B33]\]. Degree-of-spread is assigned by the NSW CCR into one of four summary stages (localised, regional, distant or unknown) \[[@B25]\]. Histology type was based on Berg groupings of ICD-O-3 classifications and grouped as adenocarcinomas, squamous cell carcinoma (SCC) or other.

*Admitted Patient Data Collection (1 July 2000 -- 30 June 2008)* - is a census of all inpatient separations from all public, private and repatriation hospitals, private day procedures centres and public nursing homes in NSW. We identified surgical resections in the separations using the International Classification of Diseases (ICD_10_AM) procedural block codes for oesophagectomy by abdominal and thoracic/cervical/transthoracic mobilisation and endoscopic mucosal resection 0858--0860 (if recorded) \[[@B34]\].

Data linkage was undertaken by a third-party, the NSW Centre for Health Record Linkage (CHeReL) using best practice privacy preserving protocols. Using probabilistic linkage, CHeReL identified all appropriate records from the APDC and CCR. They then assigned unique identifiers (or Project Person Number: PPN) to the APDC and CCR files. We received two individual data files and linked the unit-record data using the unique PPNs.

Outcomes measures and statistical analyses
------------------------------------------

We reported oesophagectomy rates for oesophageal cancer, gastro-oesophageal cancer and the combined cohort. As oesophagectomy is most beneficial for, and is associated with, non-metastatic disease and patients with adenocarcinoma, we also examined rates of surgical resection and factors associated with surgical resection and post-surgical outcomes for this sub-group of patients. Multivariate logistic regression was used to determine which factors were associated with (i) receiving an oesophagectomy and (ii) the post-resection outcomes of: longer length of hospital stay (\>28 days); 30-day complication and 30-day mortality. Post resection complications arising within 30 days were derived from ICD-10-AM diagnostic codes and included any post-procedural disorders or complications, haemorrhages, pulmonary and cardiac complications.

Cox proportional hazard regression survival analysis was also undertaken to examine one-year survival following oesophagectomy. We followed patients diagnosed with oesophageal cancer or cancer of the gastro-oesophageal junction in the NSW CCR to 31^st^ December, 2007 for death from the cancer.

We did not identify individual hospitals in this study, rather we grouped hospitals by health service (identified as Area 1 -- Area 8) and according to fiscal sector (public co-located; private co-located; public non co-located; private non co-located). We used the Charlson Comorbidity Index (CCI) to account for comorbidity before cancer diagnosis \[[@B35]\]. This index is commonly used to adjust for comorbidity and was derived from ICD-10-AM diagnostic codes as recorded in any hospital separation prior to and including the date of cancer diagnosis \[[@B36],[@B37]\]. Other covariates of interest included patient factors of age at diagnosis, gender, Australian or overseas born, tumour location and surgical procedure (where appropriate).

Statistical significance was taken at the p\<0.05 level. All statistical analysis was performed using SAS version 11.

Ethical approval
----------------

This research was approved by the NSW Population and Health Service Research Ethics Committee (2010/05/235).

Results
=======

Cohort Characteristics (Table [1](#T1){ref-type="table"})
---------------------------------------------------------

Our cohort comprised 5,024 patients, 3,456 (69%) of whom were diagnosed with oesophageal cancer and 1,568 with gastro-oesophageal cancer.

More than half of oesophageal cancer patients were ≥70 years, 67% were male, 45% were diagnosed with adenocarcinoma, 20% with regional spread and 18% with distant spread-of-disease. The vast majority (90%) of oesophageal cancer patients were defined by the CCI as having no pre-existing comorbidity. Similarly, most gastro-oesophageal patients were ≥70 years and male. Owing to the nature of gastro-oesophageal cancer, 89% of this group were diagnosed with adenocarcinoma, 35% with regional and 25% with distant disease spread. The addition of gastro-oesophageal patients to the cohort increased the proportion of patients in the overall cohort with adenocarcinoma to approximately 60%, and patients with regional or distant spread increased from 38% to 45%.

###### 

Characteristics of patients diagnosed with oesophageal (C15) and gastro-oesophageal cancer (C160)

  **Variable**                     **C15**   **C160**   **C15 & C160**                  
  -------------------------------- --------- ---------- ---------------- ------ ------- ------
  Age at diagnosis group (years)                                                         
  \<60                             657       19.0       402              25.6   1,059   21.1
  60--69                           840       24.3       399              25.4   1,239   24.7
  70--79                           1,048     30.3       486              31.0   1,534   30.5
  80+                              911       26.4       281              17.9   1,192   23.7
  Gender                                                                                 
  Female                           1,159     33.5       362              23.1   1,521   30.3
  Male                             2,297     66.5       1,206            76.9   3,503   69.7
  Country of Birth                                                                       
  Australia                        2,497     72.2       1,063            67.8   3,560   70.9
  Other                            959       37.8       505              32.2   1,464   29.1
  Histology group                                                                        
  SCC                              1,478     42.8       70               4.5    1,548   30.8
  Adenocarcinomas                  1,549     44.8       1,398            89.2   2,947   58.7
  Other                            293       8.5        79               5.0    372     7.4
  Degree of Spread                                                                       
  Localised                        1,290     37.3       435              27.7   1,725   34.3
  Regional                         692       20.0       543              34.6   1,235   24.6
  Distant                          622       18.0       387              24.7   1,009   20.1
  Unknown                          721       20.9       203              12.9   924     18.4
  Tumour location                                                                        
  Upper                            297       8.6                                297     5.9
  Middle                           470       13.8                               470     9.4
  Lower                            1,528     45.0                               1,528   30.9
  NOS\*                            1,113     32.7                               1,113   22.2
  GOJ\*                                                 1,568                   1,568   31.2
  Charlson comorbidity                                                                   
  0                                3,098     89.6       1,431            91.2   4,529   90.1
  1,2                              331       9.6        124              7.9    455     9.1
  3+                               27        0.8        13               0.8    40      0.8

\**NOS = not otherwise specified; GOJ = gastro-oesophageal junction.*

Rates of surgical resection and factors associated with receiving surgical resection (Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"})
----------------------------------------------------------------------------------------------------------------------------------------------------

The rate of resection in oesophageal cancer patients was 14.6%, whereas 26.4% of gastro-oesophageal patients underwent surgical resection. The addition of gastro-oesophageal cancer patients to the cohort increased the overall surgery rates to 18.2%.

The majority of oesophageal cancer patients who underwent resection were \<70 years (71%), male (76%), born in Australia (68%), had no pre-existing comorbidity (70%) and were diagnosed with adenocarcinoma (62%) and with loco-regional disease at the time of notification (85%). Gastro-oesophageal cancer patients had even higher proportions of males (87%) and adenocarcinoma patients (93%) who underwent resection. After adjustment for covariates, surgical resection for oesophageal cancer patients was associated with younger age (*p*\<0.001), adenocarcinoma (*p*\<0.001*)*, non-metastatic disease (*p\<*0.001), no pre-existing comorbidity (*p*=0.006) and the resection being conducted in a public or private co-located hospital (*p*\<0.001) (Table [2](#T2){ref-type="table"}). Not surprisingly the addition of gastro-oesophageal patients to the cohort increased patient numbers and resulted in some additional significant predictors of surgical resection (male gender \[aOR=1.31 95%CI 1.05-1.64\], born in Australia \[aOR=1.32, 95%CI 1.09-1.61\] and undergoing surgery at specific area health services).

###### 

Patient characteristics, location and surgery type of cohort who received resection

  **Variable**               **C15**   **C160**   **C15 & C160**                
  -------------------------- --------- ---------- ---------------- ------ ----- ------
  Oesophagectomy Yes         503       14.6       412              26.3   915   18.2
  PATIENT CHARACTERISTICS                                                       
  Age at diagnosis (years)                                                       
  \<60                       164       4.7        137              8.7    301   6.0
  60--69                     195       5.6        137              8.7    332   6.6
  70--79                     116       3.4        120              7.7    236   4.7
  80+                        28        0.8        18               1.1    46    0.9
  Gender                                                                         
  Female                     118       3.4        54               3.4    172   3.4
  Male                       385       11.1       358              22.8   743   14.8
  Country of Birth                                                               
  Australia                  345       10.0       291              18.6   636   12.7
  Other                      158       4.6        121              7.7    279   5.6
  Histology group                                                                
  SCC                        169       4.9        12               0.8    181   3.6
  Adenocarcinomas            312       9.0        385              24.6   697   13.9
  Other                      11        0.3        11               0.7    22    0.4
  Degree of Spread                                                               
  Localised                  197       5.7        123              7.8    320   6.4
  Regional                   232       6.7        239              15.2   471   9.4
  Distant                    38        1.1        35               2.2    73    1.5
  Unknown                    36        1.0        15               1.0    51    1.0
  Tumour location                                                                
  Upper                      17        0.5                                17    0.3
  Middle                     55        1.6                                55    1.1
  Lower                      331       9.6                                331   6.6
  NOS\*                      99        2.9                                99    2.0
  GOJ\*                                           412              26.3   412   8.3
  Charlson comorbidity                                                           
  0                          353       10.2       284              18.1   637   12.7
  1,2                        32        0.9        22               1.4    54    1.1
  3+                         0         0.0        2                0.1    2     0.0
  HOSPITAL CHARACTERISTICS                                                      
  Surgery type                                                                   
  Abdothoracic               79        2.3        65               4.1    144   2.9
  Abdocervical               64        1.9        45               2.9    109   2.2
  Transhiatal                360       10.4       301              19.2   661   13.2
  Hospital admission                                                             
  Private co-located         97        2.8        75               4.8    172   3.4
  Private non co-located     90        2.6        87               5.5    177   3.5
  Public co-located          182       5.3        131              8.4    313   6.2
  Public non co-located      134       3.9        119              7.6    253   5.0
  Hospital area service                                                          
  Area 1                     99        2.9        90               5.7    189   3.8
  Area 2                     107       3.1        85               5.4    192   3.8
  Area 3                     93        2.7        70               4.5    163   3.2
  Area 4                     126       3.6        90               5.7    216   4.3
  Area 5                     53        1.5        51               3.3    104   2.1
  Area 6                     11        0.3        9                0.6    20    0.4
  Area 7                     14        0.4        17               1.1    31    0.6
  Area 8                     0         0.0        0                0.0    0     0.0

\**NOS = not otherwise specified; GOJ = gastro-oesophageal junction.*

###### 

Surgery rates and factors associated with receiving surgery by topography

  **Variable**               **C15 Surgical Rate (per 100)**   **aOR**^**\#**^**(95%CI)**   **C15&C160 Surgical rate (per 100)**   **aOR (95% CI)**^**\#**^
  -------------------------- --------------------------------- ---------------------------- -------------------------------------- ---------------------------
  Age at diagnosis (years)                                                                                                          
  \<60                       25.0                              8.96 (5.63-14.3)\*           28.4                                   8.12 (5.64-11.7)\*
  60--69                     23.2                              9.85 (6.25-15.5)\*           26.8                                   8.48 (5.94-12.1)\*
  70--79                     11.1                              3.99 (2.52-6.32)\*           15.4                                   4.20 (2.94-6.00)\*
  80+                        3.1                               Referent                     3.9                                    Referent
  Gender                                                                                                                            
  Female                     10.2                              Referent                     11.3                                   Referent
  Male                       16.8                              1.04 (0.78-1.38)             21.2                                   1.31 (1.05-1.64)\*
  Country of Birth                                                                                                                  
  Australia                  13.8                              Referent                     17.9                                   Referent
  Other                      16.5                              0.90 (0.70-1.16)             19.1                                   0.76 (0.62-0.92)\*
  Histology group                                                                                                                   
  SCC                        11.4                              0.40 (0.31-0.52)\*           11.7                                   0.41 (0.32-0.51)\*
  Adenocarcinomas            20.1                              Referent                     23.6                                   Referent
  Other                      3.8                               0.28 (0.17-0.48)\*           5.9                                    0.36 (0.24-0.53)\*
  Degree of Spread                                                                                                                  
  Localised                  15.3                              6.06 (4.06-9.06)\*           18.6                                   5.50 (4.08-7.41)\*
  Regional                   33.5                              12.34 (8.22-18.52)\*         38.1                                   10.29 (7.67-13.79)\*
  Distant                    6.1                               Referent                     6.4                                    Referent
  Unknown                    5.0                               2.38 (1.42-3.98)\*           5.5                                    1.71 (1.14-2.56)\*
  Tumour location                                                                                                                   
  Upper                      5.8                               0.22 (0.12-0.39)             5.8                                    0.22 (0.13-0.40)
  Mid                        10.9                              0.51 (0.34-0.76)             10.9                                   0.52 (0.35-0.77)
  Distal                     21.5                              Referent                     21.5 26.4                              Referent 1.10 (0.88-1.36)
  Charlson comorbidity                                                                                                              
  0                          11.4                              Referent                     14.1                                   Referent
  1,2                        9.7                               0.52 (0.32-0.83)\*           11.9                                   0.56 (0.39-0.80)\*
  3+                         0                                 \-                           5.0                                    0.25 (0.06-1.14)
  Hospital admission                                                                                                                
  Private co-located         43.1                              Referent                     46.5                                   Referent
  Private non co-located     4.4                               0.06 (0.04-0.10)\*           6.2                                    0.07 (0.05-0.10)\*
  Public co-located          34.0                              0.78 (0.53-1.16)             37.8                                   0.80 (0.59-1.08)
  Public non co-located      20.6                              0.26 (0.16-0.42)\*           26.5                                   0.26 (0.18-0.38)\*
  Hospital area service                                                                                                             
  Area 1                     18.1                              2.30 (1.38-3.84)\*           23.6                                   2.99 (2.03-4.39)\*
  Area 2                     16.2                              0.73 (0.48-1.09)             19.4                                   0.80 (0.59-1.09)
  Area 3                     25.8                              Referent                     28.6                                   Referent
  Area 4                     19.6                              1.29 (0.86-1.93)             23.8                                   1.58 (1.16-2.17)\*
  Area 5                     12.2                              1.71 (0.99-2.97)             16.5                                   1.92 (1.27-2.90)\*
  Area 6                     3.5                               0.82 (0.38-1.77)             4.6                                    0.88 (0.49-1.56)
  Area 7                     5.1                               0.71 (0.34-1.47)             8.2                                    0.98 (0.59-1.65)
  Area 8                     0.0                               \-                           0.0                                    \-

^\#^*Adjusted for age-group, gender, histology, country of birth, histology, degree-of-spread, tumour location, hospital admitted, area of service, Charlson comorbidity index.*

\* Significant at P\<0.05 (two-tailed) level.

Sub-analyses of patients with non-metastatic adenocarcinoma
-----------------------------------------------------------

When restricted to the 2,155 non-metastatic adenocarcinoma patients, the addition of gastro-oesophageal cancer patients increased the overall surgery rate to 29.6% (from 26.1% for oesophageal cancer alone). Patient and hospital factors associated for surgery in this sub-cohort were the same as the entire cohort. The addition of the gastro-oesophageal patients again added the significant predictors of surgical resection (male gender \[aOR=2.03 95%CI 1.44-2.85\], being born in Australia \[aOR=1.41, 95%CI 1.35-3.44\] and undergoing surgery at specific area health services).

Outcomes following surgery (Table [4](#T4){ref-type="table"})
-------------------------------------------------------------

###### 

Patient and hospital factors associated with outcomes following surgical resection

                                     **C15**                      **C15 & C16.0**                                   
  ---------------------------------- ---------------------------- -------------------- ---------------------------- --------------------
  (**i) Length-of-stay \>28 days**   **105 (20.9)**                                    **186 (19.7)**                
  \<60 years                         23 (14.0)                    0.20 (0.08-0.53)\*   43 (14.3)                    0.24 (0.12-0.51)\*
  60--64 years                       43 (22.1)                    0.41 (0.17-1.00)     67 (20.2)                    0.43 (0.22-0.87)\*
  70--74 years                       28 (24.1)                    0.44 (0.17-1.13)     60 (25.4)                    0.57 (0.28-1.17)
  80+ years                          11 (39.3)                    Referent             16 (34.8)                    Referent
  Australian born                    75 (21.7)                    Referent             133 (20.9)                   Referent
  Overseas born                      30 (19.0)                    0.62 (0.38-1.05)     53 (19.0)                    0.67 (0.46-0.99)\*
  Private co-located                 14 (14.4)                    Referent             22 (12.8)                    Referent
  Private non co-located             11 (12.2)                    1.06 (0.43-2.63)     23 (13.0)                    1.92 (0.90-4.13)
  Public co-located                  43 (23.6)                    1.61 (0.74-3.49)     71 (22.7)                    2.10 (1.17-3.78)\*
  Public non co-located              37 (27.6)                    3.16 (0.98-10.8)     70 (27.7)                    7.89 (3.16-19.5)\*
  Area 1                             29 (29.3)                    0.91 (0.26-3.18)     52 (27.5)                    0.44 (0.17-1.10)
  Area 2                             22(20.6)                     0.91 (0.43-1.96)     43 (22.4)                    1.24 (0.70-2.19)
  Area 3                             22 (23.7)                    Referent             37 (22.7)                    Referent
  Area 4                             21 (16.7)                    0.74 (0.33-1.66)     33 (15.3)                    0.64 (0.34-1.20)
  Area 5                             8 (15.1)                     0.30 (0.07-1.26)     14 (13.5)                    0.15 (0.05-0.43)\*
  Area 6                             2 (18.2)                     0.82 (0.12-5.59)     3 (15.0)                     0.30 (0.07-1.39)
  Area 7                             1 (7.1)                      0.18 (0.02-1.92)     4 (12.9)                     0.22 (0.06-0.86)\*
  (**ii) 30 day complication**       **108 (21.5)**                                    **168 (17.0)**                
  \<60 years                         35 (21.3)                    0.40 (0.17-0.98)\*   53 (17.6)                    0.53 (0.26-1.10)
  60--64 years                       36 (18.5)                    0.33 (0.14-0.80)\*   59 (17.8)                    0.55 (0.27-1.13)
  70--74 years                       25 (21.6)                    0.39 (0.16-0.99)\*   52 (22.0)                    0.70(0.34-1.46)
  80+ years                          12 (42.9)                    Referent             14 (30.4)                    Referent
  Australian born                    71 (20.6)                    Referent             129 (20.3)                   Referent
  Overseas born                      37 (23.4)                    1.28 (0.79-2.08)     49 (17.6)                    0.87 (0.92-1.06)
  Private co-located                 16 (16.5)                    Referent             28 (16.3)                    Referent
  Private non co-located             22 (24.4)                    1.13 (0.43-2.98)     32 (18.1)                    1.07 (0.51-2.23)
  Public co-located                  40 (22.0)                    1.82 (0.87-3.78)     61 (19.5)                    1.37 (0.79-2.40)
  Public non co-located              30 (22.4)                    0.74 (0.23-2.37)     57 (22.5)                    1.47 (0.62-3.49)
  Area 1                             25 (25.3)                    3.88 (1.12-13.5)\*   40 (21.2)                    1.36 (0.54-3.47)
  Area 2                             21 (19.6)                    1.91 (0.85-4.28)     37 (19.3)                    1.40 (0.76-2.57)
  Area 3                             15 (16.1)                    Referent             28 (17.2)                    Referent
  Area 4                             29 (23.0)                    2.24 (0.99-5.09)     40 (18.5)                    1.29 (0.68-2.42)
  Area 5                             13 (24.5)                    4.01 (1.04-15.4)\*   23 (22.1)                    1.34 (0.49-3.65)
  Area 6                             9 (18.2)                     2.86 (0.43-19.1)     2 (10.0)                     0.74 (0.14-3.97)
  Area 7                             11 (21.4)                    3.87 (0.68-22.1)     8 (25.8)                     2.14 (0.66-6.91)
                                     Mortality N (rate per 100)   aHR (95%CI)          Mortality N (rate per 100)   aHR (95%CI)
  **(iv) One year survival**         **123 (24.5)**                                    **218 (23.1)**                
  \<60 years                         36 (22.0)                    0.20 (0.10-0.41)\*   64 (21.3)                    0.41 (0.23-0.74)\*
  60--64 years                       38 (30.9)                    0.19 (0.09-0.38)\*   65 (19.6)                    0.36 (0.20-0.65)\*
  70--74 years                       32 (27.6)                    0.22 (0.10-0.47)\*   68 (28.8)                    0.44 (0.24-0.81)\*
  80+ years                          17 (60.7)                    Referent             21 (45.6)                    Referent
  Australian born                    90 (26.1)                    Referent             155 (24.4)                   Referent
  Overseas born                      33 (20.9)                    0.64 (0.39-1.06)     63 (22.6)                    0.74 (0.51-1.08)
  Private co-located                 10 (10.3)                    Referent             20 (11.6)                    Referent
  Private non co-located             22 (24.4)                    1.58 (0.57-4.42)     40 (22.6)                    2.20 (1.03-4.70)\*
  Public co-located                  48 (26.4)                    1.25 (0.55-2.83)     80 (25.6)                    1.80 (0.97-3.32)
  Public non co-located              43 (32.1)                    1.34 (0.45-4.02)     78 (30.8)                    1.66 (0.71-3.89)
  Area 1                             34 (34.3)                    1.06 (0.36-3.16)     61 (32.3)                    1.28 (0.54-3.03)
  Area 2                             23 (21.5)                    0.93 (0.42-2.04)     41 (21.4)                    1.08 (0.60-1.96)
  Area 3                             25 (26.9)                    Referent             38 (23.3)                    Referent
  Area 4                             19 (15.1)                    0.73 (0.32-1.68)     38 (17.6)                    0.93 (0.49-1.76)
  Area 5                             15 (28.3)                    0.85 (0.26-2.82)     30 (28.9)                    1.67 (0.67-4.11)
  Area 6                             2 (18.2)                     1.52 (0.27-8.52)     5 (25.0)                     1.92 (0.59-6.22)
  Area 7                             5 (35.7)                     1.45 (0.36-5.87)     5 (16.1)                     0.76 (0.22-2.66)

^\#^*Adjusted for age-group, gender, histology, country of birth, degree-of-spread, tumour location, hospital admitted, area of service, Charlson comorbidity index, surgery type.*

\* Significant at the P\<0.05 (two-tailed) level.

Rates of hospital length-of-stay \>28 days (20.9% and 19.7%), 30-day mortality (3.8% and 2.7%) and one-year cancer survival (75.5% and 76.9%) were similar for oesophageal cancer and the combined cohort respectively, but differed by 4.5% for 30-day complication rates (21.5% and 17.0%). Mean one year survival time for the combined cohort was 328 days (SD 48 days).

When investigating the factors associated with longer length of hospital stay and one-year survival, the inclusion of cancer of the gastro-oesophageal junction did not alter the trends established with that of oesophageal cancer alone. However, due to increased precision, some of the associations that were not statistically significant in oesophageal cancer alone became significant in the overall cohort. For longer length of stay these factors were: being Australian born (aOR=1.49, 95%CI 1.01-2.17) and having surgery in a public co-located hospital (aOR=2.10, 95%CI 1.17-3.78). Other factors associated with length of stay \>28 days included older age (*p*\<0.001), having an admission in a public hospital (p\<0.001) and not being admitted in certain area health services. Poorer survival in the overall cohort was associated with older age (*p*\<0.001) and private non-co-located hospitals compared with private co-located hospitals (aHR=2.20, 95%CI 1.03-4.70).

We did not observe any significant associations for 30 day post-resection complication in the overall cohort. However, in the oesophageal cohort we found older age and some area health services were associated with increased complication rates. The loss of statistical significance in the overall cohort may be attributed to the lower complication rate with gastro-oesophageal cancer.

The small number of patients dying within 30-days of surgery did not permit us to perform adjusted analysis for this outcome measure.

Outcomes following surgery in patients with non-metastatic adenocarcinoma
-------------------------------------------------------------------------

Rates of hospital length-of-stay \>28 days (17.3% and 19.6%), 30-day mortality (2.4% and 2.8%), 30-day complication rates (19.0% and 19.7%) and one-year cancer survival (80.6% and 79.7%) were similar for patients with non-metastatic adenocarcinoma oesophageal cancer and the combined cohort respectively.

Factors associated with poorer post-resection outcomes in the sub-cohort were similar to those reported in all patients. However, in this group of patients with non-metastatic adenocarcinoma, we did not observe any significant associations for 30-day post-resection complication in the combined cohort or in oesophageal cancer alone.

Discussion
==========

There is an increasing use of health administrative data for research and in health policy and planning. We examined rates of oesophagectomy on oesophageal cancer patients and whether the inclusion of patients with gastro-oesophageal cancer affected oesophagectomy rates and post-resection outcomes in NSW. Unsurprisingly, the addition of gastro-oesophageal cancer patients to our cohort increased the oesophagectomy rates by 3.5%. Clearly if hospital funding is based partly on patient admissions and the volume of procedures undertaken, care must be taken to ensure that all potential 'qualifying' patients are included in any performance assessment. Our reported rate of oesophagectomy in patients is comparable to previously reported European and UK studies \[[@B30],[@B31]\] However, the UK rate has been decreasing \[[@B38]\] and may be due to the highly specialised pre- and peri-operative assessment and management required for conducting an oesophagectomy \[[@B39],[@B40]\], and the support for centralization of oesophagectomies being performed in dedicated multidisciplinary centres \[[@B41],[@B42]\].

Due to increased precision, the inclusion of gastro-oesophageal cancer resulted in an increase in the number of predictor variables associated with rates of resection and post-resection outcomes that were not seen with oesophageal cancer alone (with the exception of 30-day complication rates). For our overall cohort, factors associated with receiving an oesophagectomy included patient characteristics (age, gender, birthplace) cancer characteristics (histology, disease spread) and hospital related factors (location and funding sector); similar to previously published work \[[@B31]\]. 30-day mortality in this study was low, in-line with previous studies and international benchmarks \[[@B9],[@B38],[@B43]\]. We found that patients undergoing surgical resection in public hospitals were more likely to have a length of stay \>28 days. This may reflect the epidemiology of oesophageal and gastro-oesophageal cancer and that more complex cases are treated in public hospitals (teaching hospitals linked to academic centres in Australia). Thus, the addition of gastro-oesophageal cancer did impact on factors associated with receiving an oesophagectomy and on some post-surgery outcomes.

One-year cancer survival was worse in those who underwent surgery in private hospitals that were not co-located with public hospitals, potentially indicating the benefits of surgery being conducted in higher volume or teaching hospitals \[[@B7],[@B9],[@B18],[@B21],[@B30],[@B41],[@B44],[@B45]\].

Our current study demonstrated a reduced 30-day complication rate in gastro-oesophageal cancer compared with oesophageal cancer, hence statistical associations tended towards the null in the combined cohort. This may have been due to the slightly higher rate of transhiatal oesophagectomies undertaken for adenocarcinoma, compared with that in oesophageal cancer and hence lower peri-operative morbidity \[[@B46]\], however the only factors which were significantly associated with higher complication rate in patients with oesophageal cancer were older age and resection being conducted in some area health services.

Although we attempted to account for comorbidity with the use of the CCI, the proportion of patients with comorbidity preceding cancer diagnosis was low and as aforementioned, due to how CCI is calculated, comorbidity was most likely under-ascertained. The under-reporting of comorbidities in administrative data may be due to incomplete data transposition from medical records in individual hospitals to administrative databases \[[@B47]-[@B49]\]. Further, non-surgical treatments such as chemotherapy and radiotherapy are funded by the PBS and MBS respectively and this data is not linked routinely to hospital morbidity data thus it was not available for this population linkage study. Further, the only measure of disease severity available was degree-of-spread at diagnosis; there were no indicators of performance status available.

Conclusion
==========

Oesophagectomy in NSW is performed with good outcomes. Our own experience highlights the need for identifying the appropriate patient populations under study and their unique contributions to the overall cohort, given the change in surgical resection rate and longer length-of-stay post-resection with the inclusion of gastro-oesophageal cancer. The measurement of hospital performance is a powerful tool to stimulate quality improvement, transparency and accountability and health administrative data sets have become pivotal to this activity.
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